



9025 N Sam Houston Pkwy E, Ste 105, Humble, TX 77396 · (832) 777-1467

Tirzepatide (Mounjaro/Zepbound) Informed Consent

INITIAL EACH STATEMENT

Patient _____

DOB _____

Phone _____

Provider _____

Date _____

TREATMENT OVERVIEW

Tirzepatide is a dual GIP/GLP-1 receptor agonist used for chronic weight management. Treatment should be combined with diet and exercise. Results vary.

PLEASE INITIAL EACH STATEMENT

- ☐ I understand weight loss is not guaranteed.
- ☐ I understand common side effects include nausea, vomiting, diarrhea, constipation, decreased appetite and injection-site reactions.
- ☐ I understand serious risks include pancreatitis, gallbladder disease, dehydration, kidney injury, allergic reactions and delayed gastric emptying.
- ☐ I understand this medication has an FDA boxed warning regarding thyroid C-cell tumors and should not be used with a personal/family history of medullary thyroid carcinoma or MEN2.
- ☐ I am not pregnant or breastfeeding and will notify my provider immediately if pregnancy occurs.
- ☐ I have disclosed my medical history, medications, allergies and supplements.
- ☐ I understand to seek emergency care for severe abdominal pain, persistent vomiting, facial swelling, trouble breathing or vision changes.
- ☐ I have had the opportunity to ask questions and consent voluntarily.

CONSENT

I understand the risks, benefits, alternatives, expected outcomes, and financial responsibility. No guarantees have been made regarding results.

Patient Signature

Provider Signature

Date

Date
